HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

ISPC

iSpecimen Inc. (NASDAQ)

Healthcare — Diagnostics & Research

iSpecimen Inc. operates marketplace that provides biospecimens to life science researchers in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. The company's marketplace offers human biospecimens, including biofluids, such as whole blood, plasma, serum, urine, saliva, sputum, nasopharyngeal material, and cerebral spinal fluid; solid tissue comprising fresh, fixed, and cryopreserved tissue, as well as formalin-fixed paraffin embedded blocks, slides, and curls; and hematopoietic stem and immune cells, including bone marrow, cord blood, whole blood, or sub-components of these tissues, such as peripheral blood mononuclear cells and other isolated cell types. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. iSpecimen Inc. was incorporated in 2009 and is headquartered in Woburn, Massachusetts.

None
$2.73
+$0.08 (+3.02%)
Sign in to add ISPC to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$3.92M
P/E Ratio (TTM)-
Forward P/E-3.46
EPS (TTM)$-329.05
Dividend Yield-
Profit Margin-
Revenue Growth-85.20%
ROE-894.59%
Debt/Equity31.32
Recommendation None
Analyst Target-
Analysts-
Indexes NASDAQ

Technical Indicators

RSI (14)52.0
Beta1.62
SMA 20-
SMA 40-
52-Week High$127.20
52-Week Low$2.39
50-Day Avg$3.80
200-Day Avg$16.34
Avg Volume872.0K
Volume31.9K

Performance Analysis

NEUTRAL

ISPC presents a mixed picture with both positive and negative indicators.

+ Trading near its 52-week low ($2.39), which could present a value opportunity.
~ RSI at 52.0 is in neutral territory.
- Price is below both the 50-day and 200-day moving averages — in a downtrend.
- Revenue declined 85.2% year-over-year.
~ Wall Street consensus is "none".

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 13:15 UTC

Back to Screener Export Report